<DOC>
	<DOCNO>NCT00085449</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , monoclonal antibody , radiation therapy donor peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell exactly match patient 's blood . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase I/II trial study side effect alemtuzumab , fludarabine , melphalan without cyclosporine , mycophenolate mofetil , total-body irradiation donor peripheral blood stem cell transplant see well work treat patient relapsed refractory hematologic cancer .</brief_summary>
	<brief_title>Alemtuzumab Plus Fludarabine Melphalan With Without Cyclosporine , Mycophenolate Mofetil , Low-Dose Total-Body Irradiation Therapy Followed Donor Peripheral Stem Cell Transplant Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine ability reduced-intensity condition regimen comprise alemtuzumab , fludarabine , melphalan without cyclosporine , mycophenolate mofetil , low-dose total body radiotherapy follow haplotype-mismatched , KIR class I epitope-mismatched CD34-positive allogeneic peripheral blood stem cell transplantation facilitate engraftment day 35 post-transplantation least 85 % patient relapse , refractory , poor-risk hematological malignancy . - Determine risk graft-versus-host-disease patient treat regimen . - Determine , preliminarily , efficacy regimen , term progression-free survival , patient . - Correlate outcome , engraftment , progression-free survival number detectable alloreactive natural killer cell clone transplantation engraftment patient treat regimen . - Determine immune reconstitution patient treat regimen . OUTLINE : This multicenter , pilot study . Patients initially treat condition regimen A . If adequate donor engraftment achieve , subsequent patient treat condition regimen B . - Conditioning regimen A : Patients receive alemtuzumab IV 2 hour day -14 -12 ; fludarabine IV 30 minute day -7 -3 ; melphalan IV 20-30 minute day -2 . - Conditioning regimen B : Patients receive oral IV cyclosporine twice daily oral IV mycophenolate mofetil twice daily day -15 0 . Patients also receive alemtuzumab , fludarabine , melphalan condition regimen A . Patients undergo low-dose total body irradiation twice daily day -2 -1 . All patient undergo allogeneic , T-cell-depleted , CD34-positive peripheral blood stem cell transplantation day 0 . Patients receive sargramostim ( GM-CSF ) subcutaneously begin day 1 continue blood count recover . Patients follow every 3 month 1 year every 6 month 5 year . PROJECTED ACCRUAL : A total 14-56 patient ( 14-28 per regimen ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hematological malignancy 1 follow type : Acute myeloid leukemia meeting least 1 follow criterion : Poorrisk cytogenetics , include 5 , 5q , 7 , 7q , 11q23 , Philadelphia ( Ph ) chromosomepositive first subsequent complete remission ( CR ) Relapsed primary refractory disease ≤ 10 % blast peripheral blood ≤ 20 % blast bone marrow Standardrisk cytogenetics second CR AND autologous transplantation feasible Standardrisk cytogenetics third subsequent CR Acute lymphoblastic leukemia meeting 1 follow criterion : Second subsequent CR Highrisk cytogenetics , include Ph chromosomepositive ( 4:11 ) first CR Relapsed primarily refractory disease ≤ 10 % blast peripheral blood ≤ 20 % blast bone marrow Highrisk myelodysplasia International Prognostic Scoring System Score ≥ 2.5 Chronic myeloid leukemia ( CML ) * inadequate response imatinib meeting 1 follow criterion : Second subsequent chronic phase Accelerated phase NOTE : *Patients CML blast crisis ( &gt; 30 % promyelocytes myeloblasts bone marrow ) eligible NonHodgkin 's lymphoma meeting 1 follow criterion : Primarily refractory disease refractory relapse Relapsed disease autologous stem cell transplantation Chemosensitive relapse disease without CR standard salvage therapy AND option autologous stem cell transplantation due blood marrow involvement failure harvest sufficient autologous stem cell Chronic lymphocytic leukemia meeting follow criterion : Stage III IV disease Refractory fludarabine Multiple myeloma meeting 1 follow criterion : Primarily refractory disease refractory relapse Relapsed disease autologous stem cell transplantation No relapse disease &lt; 6 month autologous stem cell transplantation No available eligible HLAmatched ( i.e. , 5 6 6 6 antigen match HLAA , B , DR locus ) family donor serological molecular type Available suitable family donor meeting follow criterion : Parent , sibling , child recipient ≥ 16 year age Identical one HLA haplotype ( i.e. , haploidentical ) AND incompatible HLAA , B , C , DR locus unshared haplotype serological molecular type Mismatched respect KIR class I epitopes graftvshost directional activity Mismatching predict graftvshost hostvsgraft bidirectional activity eligible No mismatching predict hostvsgraft directional activity PATIENT CHARACTERISTICS : Age 18 60 Performance status ECOG 01 Hepatic Bilirubin &lt; 2 time upper limit normal ( ULN ) AST ALT &lt; 2 time ULN Renal Creatinine ≤ 2 mg/dL Cardiovascular LVEF &gt; 40 % ( correct ) Pulmonary DLCO &gt; 50 % predict Other No active infection require oral IV antibiotic HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy Concurrent corticosteroid allow adrenal failure , treatment graftvshost disease , premedication study No concurrent corticosteroid antiemesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>